Endodiag

Endodiag, which specialises in developing innovative solutions for diagnosing endometriosis, a little-understood but very common condition affecting women, has welcomed Crédit Mutuel Innovation and BNP Paribas Développement as equity investors.

Endodiag is a biotech company that is aiming to improve the diagnosis and care of women suffering from endometriosis. Endometriosis is a chronic gynaecological condition that affects 10% of women of child-bearing age, i.e. around 180 million women worldwide. Its main symptoms are severe and chronic pelvic pain and infertility in 40% of cases. Endometriosis is a condition in which tissue from the lining of the womb (endometrium) migrates to the abdominal cavity, causing lesions and/or adhesions in the colonised organs and/or ovarian cysts. Currently, the only reliable method of diagnosis involves analysing lesions removed using laparoscopy, a surgical procedure carried out under general anaesthetic, and the average time taken to diagnose the condition is 9 years. There is currently no other safe diagnostic method that allows the condition to be identified more quickly and patients to be treated at an earlier stage. The economic impact of the condition is huge, estimated at $78 billion in Europe and $77 billion in the USA.

Endodiag has a portfolio of innovative products that aim to detect the condition and care for patients using personalised medicine approaches. The aim of the EndoDtect® project is to allow early diagnosis of endometriosis using blood samples. EndoGram® aims to analyse the condition in each patient, involving a test that helps determine the risk of recurrence, allows personalised monitoring and helps surgeons select the most effective way of caring for the patient. Endodiag also wants to help develop new associated companion treatments and diagnostic tests, using its unique biobank of biological endometriosis samples, the associated clinical data and its expertise in the condition. It has already signed two partnership agreements with biotechnology companies.

The recent funding round was intended to finance the clinical validation of EndoDtect® and prepare for its introduction into the market, and to continue the development of the other projects in Endodiag's pipeline.

"This funding round allows us to step up the clinical validation of our projects and therefore gives us the opportunity to radically change the lives of millions of women suffering from this condition through simpler and quicker diagnosis and improved care," said Cécile Real, Co-Founder and Chairman of Endodiag. "We are delighted to welcome Crédit Mutuel Innovation (formerly CM-CIC Innovation) and BNP Paribas Développement, alongside our long-standing investor Medevice Capital, to support us as we step up development and prepare to bring our products to market," added Cécile Real.

"We were attracted by Endodiag's team and vision. The company wants to bring about a radical change in the provision of care for endometriosis, a little-understood and highly debilitating condition. We have known the team for a long time, we share the same values and we have every confidence in their ability to hit their development targets and therefore meet the needs of patients," explains Karine Lignel, Chief Executive Officer of Crédit Mutuel Innovation.

"We decided to invest because of Endodiag's unique approach, particularly its desire to gain a holistic understanding of this condition, about which too little is known even today. It is highly debilitating and there are no effective diagnostic solutions or therapies for it, despite the very large numbers of patients affected," added Cyrus Contant, Associate at Crédit Mutuel Innovation.

"Endodiag has led the way in raising the profile of this widespread but often-ignored condition. We are proud to be supporting its brilliant and dedicated team as they write the next chapters in this story," added Anne Toupé, Principal in Venture Capital at BNP Paribas Développement.

Contact us